ASCLETIS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 HKD | -1.47% |
|
+4.69% | -8.22% |
| 04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
| 04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Evolution of the average Target Price on Ascletis Pharma Inc.
Price target over the last 5 years
History of analyst recommendation changes
648b953a51356705c97cc860940d9e76.f9d3dEIPMs8Cc1Q6cuTK2BiEdyNpZPNntmS1qksviMg.GIdCPS97a_4vFHlVOYK4knnwEFo6V8Yw_FOYmzFC8bEpkkQmdVx1mEQ7FQ~da0b9091cb15231df42e1f4171a58d3c
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.24
CNY
Average target price
2.752
CNY
Spread / Average Target
+121.86%
High Price Target
3.513
CNY
Spread / Highest target
+183.22%
Low Price Target
1.991
CNY
Spread / Lowest Target
+60.51%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- 1672 Stock
- Consensus Ascletis Pharma Inc.
